| HOME >> BIOLOGY >> TECHNOLOGY |
BRISBANE, Calif., Aug. 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, President and Chief Executive Officer of InterMune, will present at the Thomas Weisel Healthcare Conference in Boston on September 5, 2007 at 3:50 p.m. EDT. Mr. Welch will also present at the Bear Stearns 20th Annual Healthcare Conference in New York City on September 11, 2007 at 3 p.m. EDT.
To access a live audio webcast of the presentations, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research,
development and commercialization of innovative therapies in pulmonology
and hepatology. InterMune has a pipeline portfolio addressing idiopathic
pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The
pulmonology portfolio includes the Phase 3 program, CAPACITY, which is
evaluating pirfenidone as a possible therapeutic candidate for the
treatment of patients with IPF and a research program focused on small
molecules for pulmonary disease. The hepatology portfolio includes the HCV
protease inhibitor compound ITMN-191 (referred to as R7227 within the Roche
research and development programs) in Phase 1a, a second-generation HCV
protease inhibitor research program, and a research program evaluating a
new target in hepatology. For additional information about InterMune and
its R&D pipeline, please visit
| SOURCE InterMune, Inc. Copyright©2007 PR Newswire. All rights reserved |